ArticleFrontiers in public health2026
Cost-effectiveness analysis of first-line gefitinib plus anlotinib treatment for patients with stage IIIB-IV EGFR-mutated NSCLC in China.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The FL-ALTER study introduces a novel first-line therapeutic approach for patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). This study aimed to evaluate the cost-effectiveness of first-line gefitinib plus anlotinib for Chinese patients diagnosed with stage IIIB-IV EGFR-mutant NSCLC. Methods: A combined decision-tree and Markov model was constructed to predict 5-year cost-effectiveness using follow-up data from the FL-ALTER trial. Efficacy and safety inputs were derived from randomized clinical trials, whereas cost and utility values were sourced from published literature. Incremental cost-effectiveness ratios (ICERs) were calculated from the perspective of the Chinese healthcare system. Furthermore, scenario analyses were performed to evaluate the economic impact of patient assistance programs (PAPs) and drug price negotiations. Results: Compared with gefitinib plus placebo, first-line gefitinib plus anlotinib yielded an additional 0.16 quality-adjusted life years (QALYs), with an incremental cost-effectiveness ratio (ICER) of $196,652.56/QALY. Deterministic sensitivity analysis revealed that the utility of progression-free survival and the cost of anlotinib were the most influential parameters driving the model outcomes. Probabilistic sensitivity analysis indicated that the combination regimen had no cost-effectiveness advantage at the current Chinese willingness-to-pay (WTP) threshold of $38,043.34/QALY. Conclusion: Within the Chinese healthcare system, first-line gefitinib plus anlotinib is not cost-effective for advanced EGFR-mutated NSCLC at a WTP threshold of $38,043.34/QALY. However, implementing a PAP or price negotiation for anlotinib could effectively lower incremental costs, rendering this regimen a more economically viable clinical option.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.